Vascular Access Conversation - IVUPDATE Podcast from IVTEAM

"Building home infusion CLABSI surveillance programs will require support from home infusion leadership" Hannum et al (2022).

CLABSI surveillance in home infusion therapy

Abstract:

Background: Barriers for home infusion therapy central line associated bloodstream infection (CLABSI) surveillance have not been elucidated and are needed to identify how to support home infusion CLABSI surveillance. We aimed to (1) perform a goal-directed task analysis of home infusion CLABSI surveillance, and (2) describe barriers to, facilitators for, and suggested strategies for successful home infusion CLABSI surveillance.

Methods: We conducted semi-structured interviews with team members involved in CLABSI surveillance at 5 large home infusion agencies to explore work systems used by members of the agency for home infusion CLABSI surveillance. We analyzed the transcribed interviews qualitatively for themes.

Results: Twenty-one interviews revealed 8 steps for performing CLABSI surveillance in home infusion therapy. Major barriers identified included the need for training of the surveillance staff, lack of a standardized definition, inadequate information technology support, struggles communicating with hospitals, inadequate time, and insufficient clinician engagement and leadership support.

Discussion: Staff performing home infusion CLABSI surveillance need health system resources, particularly leadership and front-line engagement, access to data, information technology support, training, dedicated time, and reports to perform tasks.

Conclusions: Building home infusion CLABSI surveillance programs will require support from home infusion leadership.


Reference:

Hannum SM, Oladapo-Shittu O, Salinas AB, Weems K, Marsteller J, Gurses AP, Cosgrove SE, Keller SC. A task analysis of central line-associated bloodstream infection (CLABSI) surveillance in home infusion therapy. Am J Infect Control. 2022 Feb 22:S0196-6553(22)00042-6. doi: 10.1016/j.ajic.2022.01.008. Epub ahead of print. PMID: 35341660.